Concepedia

Jennifer Lauchle

JL

Statistics

Publications

16

Citations

1.2K

H-Index

15

Active since

2004

Affiliations

University of California, San Francisco(Current)

Dana-Farber Cancer Institute

Memorial Sloan Kettering Cancer Center

Tennessee Oncology

The University of Texas Southwestern Medical Center

Jennifer Lauchle is an author at University of California, San Francisco specializing in medicine, oncology, and molecular oncology.

ORCID

Publications per year

2004–2023

16

Publications

16

Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder

Doan Le, Namie Kong, Yuan Zhu et al. · Blood · 2004 · 174 citations · Full text

, , +8

Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras

Jennifer Lauchle, Doris Kim, Doan Le et al. · Nature · 2009 · 150 citations

, , +10

Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors

Saoirse Dolly, Andrew J. Wagner, Johanna C. Bendell et al. · Clinical Cancer Research · 2016 · 134 citations · Full text

, , +16

Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice

Tiffany Chang, Kimberly Krisman, Emily Harding Theobald et al. · Journal of Clinical Investigation · 2012 · 120 citations · Full text

, , +17

A multicenter, single‐arm, open‐label, phase 2 study of apitolisib (GDC‐0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study)

Vicky Makker, Fernando O. Recio, Ling Ma et al. · Cancer · 2016 · 97 citations · Full text

, , +10

1–5 of 16